GHSI earnings
Guardion Health Sciences Inc. (GHSI) earnings releases and earnings dates - real-time wire coverage of every quarterly report.
Recent earnings items
- Guardion Health Sciences Announces Financial Results for the Three Months and Six Months Ended June 30, 2024Guardion Also Provides an Update to Stockholders of Significant Recent Developments HOUSTON, TEXAS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company"), a clinical nutrition company that offers science-based, clinically supported products designed for consumer ocular health, today announced its financial results for the three months and six months ended June 30, 2024, as described below. The Company also provided an update to stockholders of significant recent developments. Recent Developments: Sale of Viactiv® Brand and Business On May 31, 2024, as previously disclosed publicly, the Company completed the sale of all of t
- Guardion Health Sciences Announces-- Financial Results for the Three Months Ended March 31, 2024 -- Institutional Shareholder Services Issues Report Recommending that Institutional Stockholders Vote in Favor of All Proposals at the Upcoming Special Meeting of Stockholders on May 23, 2024 Board of Directors Urges Stockholders to Vote to Approve the Sale of the Company's Viactiv Brand and Business and Plan of Liquidation and Dissolution If both proposals are approved, stockholders would receive one or more liquidating cash distributions, which combined are expected to represent a premium over our recent stock price HOUSTON, TEXAS, May 13, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:G
- Guardion Health Sciences Announces Financial Results for the Year Ended December 31, 2023Viactiv® Product Line Generated Net Revenues of Approximately $11.9 Million for the Year Ended December 31, 2023, an Increase of Approximately 12% as Compared to the Year Ended December 31, 2022 HOUSTON, TEXAS, March 29, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company"), a clinical nutrition company that offers a portfolio of science-based, clinically-supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients, announced its financial results for the year ended December 31, 2023. The Company also provided a corporate update to stockholders. Financial highlights for the ye
- Guardion Health Sciences Announces Financial Results for the Three Months and Nine Months Ended September 30, 2023Viactiv® Generated Net Revenues of Approximately $3.3 Million for the Three Months Ended September 30, 2023, an increase of 27% over the Three Months Ended September 30, 2022 HOUSTON, TEXAS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company"), a clinical nutrition company that offers a portfolio of science-based, clinically-supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients, announced its financial results for the three months and nine months ended September 30, 2023. The Company also provided a corporate update to stockholders. Financial highlights fo
- Guardion Health Sciences Announces Financial Results for the Three Months and Six Months Ended June 30, 2023HOUSTON, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company"), a clinical nutrition company that offers a portfolio of science-based, clinically-supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients, announced its financial results for the three months and six months ended June 30, 2023. The Company also provided a corporate update to stockholders. Financial highlights for the three months and six months ended June 30, 2023 include the following (all common share and per share amounts shown below have been adjusted to reflect the 1-for-50 reverse stock split ef
- Guardion Health Sciences Announces Financial Results for the Quarter Ended March 31, 2023HOUSTON, May 15, 2023 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company"), a clinical nutrition company that offers a portfolio of science-based, clinically-supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients, announced its financial results for the three months ended March 31, 2023. The Company also provided a corporate update to stockholders. Financial and other highlights for the three months ended March 31, 2023 include the following (all common share and per share amounts shown below have been adjusted to reflect the 1-for-50 reverse stock split effective Janua
- Guardion Health Sciences Announces Financial Results for the Year Ended December 31, 2022HOUSTON, April 17, 2023 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company"), a clinical nutrition company that offers a portfolio of science-based, clinically-supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients, announced its financial results for the year ended December 31, 2022. The Company also provided a corporate update to stockholders. Financial and other highlights for the year ended December 31, 2022 include the following (all common share and per share amounts shown below have been adjusted to reflect the 1-for-50 reverse stock split effective January 6, 2023):
- Guardion Health Sciences Announces Financial Results for the Three Months and Nine Months Ended September 30, 2022Viactiv® Generated Net Revenues of Approximately $2.6 Million or 96% of Net Revenues for the Quarter Ended September 30, 2022 Company Announces Program to Evaluate Strategic Alternatives HOUSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company"), a clinical nutrition company that offers a portfolio of science-based, clinically-supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients, announced its financial results for the three months and nine months ended September 30, 2022. The Company also provided a corporate update to stockholders. Financial highlights
- Guardion Health Sciences Announces Financial Results for the Year Ended December 31, 2021June 2021 Acquisition of Viactiv® Brand and Business Changed Operational Focus of Company and Materially Impacted 2021 Revenues, Operations and Financial Results Viactiv® Generated Net Revenues of approximately $2.4 Million or 92% of Net Revenues for the Quarter Ended December 31, 2021, and approximately $6.5 Million or 90% of Net Revenues for the Year Ended December 31, 2021 HOUSTON, April 01, 2022 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company"), a clinical nutrition company that develops clinically supported nutrition, medical foods, and dietary supplements, announced its financial results for the year ended December 31, 2021. The Company
- Guardion Health Sciences Announces Financial Results for the Three Months Ended September 30, 2021HOUSTON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company"), a clinical nutrition and diagnostics company that develops clinically supported nutrition, medical foods, supplements and medical devices, announced its financial results for the three months and nine months ended September 30, 2021. The Company also provided a corporate update to shareholders. Financial highlights for the three months ended September 30, 2021 include the following: Total revenue of $3,148,612 for the three months ended September 30, 2021, as compared to $253,188 for the three months ended September 30, 2020, reflecting the first full quarter
- Guardion Health Sciences Announces Financial Results for the Three Months Ended June 30, 2021, including $1,000,000+ of Sales from Viactiv® Products in the First Month of Guardion's OwnershipHOUSTON, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company"), a clinical nutrition and diagnostics company that develops clinically supported nutrition, medical foods, supplements and medical devices, announced its financial results for the three months and six months ended June 30, 2021. The Company also provided a corporate update and overview of growth plans to shareholders. Financial highlights for the three months ended June 30, 2021, include the following: Total revenue of $1,223,720 for the three months ended June 30, 2021, as compared to $1,190,909 for the three months ended June 30, 2020, an increase of approximately 3
- Guardion Health Sciences Announces Financial Results for the Three Months Ended March 31, 2021SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company"), a clinical nutrition and diagnostics company that develops clinically supported nutrition, medical foods, supplements and medical devices, announced financial results for the three months ended March 31, 2021 and is also providing a corporate update for shareholders. Effective March 1, 2021, the Company effectuated a 1-for-6 reverse split of its outstanding common stock. Accordingly, all share and per share amounts included herein have been retroactively adjusted to reflect the reverse stock split for all periods presented. Financial highlights for the quarter ended Mar
- Guardion Health Sciences Announces Financial Results for the Three Months and Year Ended December 31, 2020SAN DIEGO, March 26, 2021 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a clinical nutrition and diagnostics company that develops science-based, clinically supported nutritional supplements, medical foods, and diagnostic products, announced financial results for the three months and year ended December 31, 2020. Effective March 1, 2021, the Company amended its Certificate of Incorporation to effectuate a 1-for-6 reverse split of its outstanding common stock. Accordingly, all share and per share amounts included herein have been retroactively adjusted to reflect the reverse stock split for all periods presented. Financial highlights for